Remepy is Pioneering Hybrid Drugs™.
We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™.
Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug.
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance.
Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
-
Industry
-
Biotechnology Research
-
Company size
-
11-50 employees
-
Headquarters
-
Ramat Gan
-
Type
-
Privately Held
-
Founded
-
2022
-
Specialties
-
Pharma, Biotech, Digital Health, Software, mobile apps, immunology, drug development, oncology, and Neurology